Mineral metabolism in postmenopausal women and men over 50 years. Pharmacogenetics in the Camargo cohort

Osteoporosis is the most prevalent bone disease, characterized by a decrease bone mineral density (BMD) and therefore a greater susceptibility to fractures. This bone disorder has an important hereditary component. Therefore the involved genetic variants will allow to establish new preventive measures at an early stage and even improve the response to drugs. The aim of this study was to determine if common variants of genes that may be influencing drug responses.
An article has been recently published in the journal ‘Pharmaceutics’, entitled ‘Pharmacogenetics of
Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs’, with the genotyped data in this project. However, to obtain more information on polygenic risk and other
approaches, we need new samples from general population to compare with those previously diagnosed with osteoporosis. There is an important polygenic component in osteoporosis. Hence, there are various polygenic risk scores (PRS) associated with BMD and bone fractures.
Many of these PRS are based on the European population, but none on the Spanish population. Therefore, the objective of this study is to analyze the ability of these PRS to predict osteoporosis in the Spanish population. And also to compare the Spanish population with each other to find new markers involved in the disease.
This is a case-control study nested within the Carmargo cohort.